Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 18 04:00PM ET
9.03
Dollar change
-0.09
Percentage change
-0.99
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y- Shs Outstand Perf Week-10.95%
SponsorElevate Shares ETF Type Tagssingle-asset Return% 3Y- Total Holdings10 Perf Month-20.86%
Fund Family Bond Type Tagsoptions Return% 5Y- AUM21.71M Perf Quarter-46.88%
Index- Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y-55.56%
Index Weighting Commodity Type Tagscovered-call Return% SI NAV/sh Perf Year-
Active/Passive Quant Type Tags- Flows% 1M18.44% 52W Range8.39 - 26.00 Perf YTD-61.73%
Dividend TTM8.80 (97.48%) ESG Type Tags- Flows% 3M67.72% 52W High-65.27% Beta-
Dividend Ex-DateSep 06, 2024 Dividend Type Sector/Theme Flows% YTD- 52W Low7.63% ATR (14)0.44
Expense0.99% Structure Type Region Flows% 1Y RSI (14)30.66 Volatility4.17% 3.18%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.56 Prev Close9.12
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume69.43K Price9.03
SMA20-10.39% SMA50-25.80% SMA200-50.00% Trades Volume38,989 Change-0.99%
YieldMax MRNA Option Income Strategy ETF seeks current income; exposure to the share price of the common stock of Moderna, Inc. ("MRNA"), subject to a limit on potential investment gains is the secondary consideration. The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.